Kolexia
Giltat Aurelien
Hématologie
Hôpital Larrey Angers
Angers, France
54 Activités
0 Followers

Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Leucémies Leucémie aigüe myéloïde Leucémie myéloïde Lymphomes Syndromes myélodysplasiques Maladie du greffon contre l'hôte Hypertension artérielle Syndrome inflammatoire de restauration immunitaire Ostéoporose

Industries

MSD
1 collaboration(s)
Dernière en 2022
AstraZeneca
1 collaboration(s)
Dernière en 2021
{{person.topindus3.name}}
{{person.topindus3.tot}} collaboration(s)
Dernière en {{person.topindus3.last}}
{{person.topindus4.name}}
{{person.topindus4.tot}} collaboration(s)
Dernière en {{person.topindus4.last}}

Dernières activités

Toxicity Profile According to Etoposide and Cytarabine Dosing in Patients with Lymphoma Receiving Autologous Stem Cell Transplantation Following BEAM Conditioning.
Annals of hematology   28 juin 2023
Beaupréau-en-Mauges. « Leucémie espoir finance des soins de support
Courrier de l'Ouest   30 mai 2023
Implementation of a new blood cultures sampling strategy in patients receiving intensive chemotherapy for acute leukemia and/or hematopoietic cell transplantation.
Leukemia & lymphoma   13 avril 2023
Relationship between comorbidities, mutational profile, and outcome after intensive chemotherapy in patients older than 60 years with acute myeloid leukemia: Assessment of different risk scores.
American journal of hematology   05 avril 2023
Retrospective, real-life study of venetoclax plus azacitidine or low-dose cytarabine in French patients with acute myeloid leukemia ineligible for intensive chemotherapy.
Cancer medicine   08 décembre 2022
Prevalence of Osteoporosis in Myelodysplastic Syndrome Patients and Association with Cytopenias
Annual Meeting Abstracts 2022   15 novembre 2022
Graft failure, poor graft function erythroblastopenia: Actualization of definitions, diagnosis and treatment: Guidelines from the SFGM-TC.
Bulletin du cancer   25 octobre 2022
Progressive multifocal leukoencephalopathy after durvalumab treatment for acute myeloid leukemia: A consequence of an immune reconstitution inflammatory syndrome?
EJHaem   29 mai 2022
Daunorubicin and Its Active Metabolite Pharmacokinetic Profiles in Acute Myeloid Leukaemia Patients: A Pharmacokinetic Ancillary Study of the BIG-1 Trial.
Pharmaceutics   05 avril 2022
20. Soins de support | éthique | sciences humaines
Hématologie Congress 2022   30 mars 2022